ArticleDie Naturwissenschaften2026
Study on the mechanism of Ershiwei Chenxiang Pills in the treatment of high altitude hypertension based on network pharmacology and molecular docking analysis.
Article in Die Naturwissenschaften, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ershiwei Chenxiang Pill (ECP) is effective in treating cardiovascular diseases including hypertension. High-altitude hypertension (HAH) is pathophysiologically distinct from general hypertension, primarily due to chronic hypoxia-induced mechanisms such as aberrant activation of the hypoxia-inducible factor (HIF) pathway and altered vascular remodeling. The molecular mechanism of ECP against HAH remains unclear. This study aims to elucidate this mechanism using network pharmacology and molecular docking. The effective components and target proteins of ECP were screened by the TCMSP database and TCMID database. The HAH genes were retrieved from NCBI, OMIM, and GeneCards databases. Protein-protein interaction (PPI) network was constructed to screen core targets. The distribution of the target in the organ was also assessed. The GO and KEGG enrichment analysis was carried out by the DAVID6.8 database. Finally, AutoDock 4.2.6 software was used for molecular docking verification. A total of 125 active components and 308 potential targets from ECP were identified, with 57 overlapping targets with HAH. PPI analysis revealed 14 key targets. GO analysis yielded 397 biological processes, 39 cellular components, and 52 molecular functions. KEGG analysis identified 207 pathways, among which the HIF-1 signaling pathway, Fluid shear stress and atherosclerosis were highlighted as most biologically relevant to HAH. Molecular docking confirmed strong binding affinities between four key components (apigenin, (-)-epigallocatechin-3-gallate, chrysoeriol, baicalein) and six core targets (VEGFA, PPARG, HIF1A, ESR1, MMP9, CAV1), with binding energies ranging from − 6.7 to -9.2 kcal/mol. This study systematically reveals that ECP may treat HAH through multi-component, multi-target, and multi-pathway mechanisms, with a core emphasis on modulating hypoxia-responsive pathways (e.g., HIF-1) and vascular function. These findings offer novel insights into the mechanistic basis of ECP in HAH treatment and provide a foundation for further experimental validation.
Indexed as
Identifiers
41591503What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.